Tarlatamab for SCLC Brain Metastases

A single arm phase II study evaluating intracranial efficacy of tarlatamab in patients with asymptomatic active brain metastases from small cell lung cancer (SCLC).

Trial Details

NCT ID
NCT07402343
Phase
PHASE2
Sponsor
Maastricht University Medical Center
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Tarlatamab
Locations (sample)
  • Amsterdam, Netherlands|52.37403,4.88969
  • Groningen, Netherlands|53.21917,6.56667
  • Maastricht, Netherlands|50.84833,5.68889
  • Rotterdam, Netherlands|51.9225,4.47917

Key Eligibility Criteria

  • In order to be eligible to participate in this study, a subject must meet all of the following criteria:
  • Signed and written informed consent
  • Age 18 years or older
  • Patients with pathology proven metastatic SCLC

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →